Acura Pharmaceuticals Inc (ACUR) financial statements (2021 and earlier)

Company profile

Business Address 616 N. NORTH COURT, SUITE 120
PALATINE, IL 60067
State of Incorp. NY
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Receivables  00001
Other undisclosed current assets1221110
Total current assets:1221111
Noncurrent Assets
Nontrade receivables    000
Property, plant and equipment0011111
Intangible assets, net (including goodwill)0000111
Intangible assets, net (excluding goodwill)0000111
Total noncurrent assets:1111112
TOTAL ASSETS:2232322
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1111111
Accounts payable0000001
Accrued liabilities1111111
Debt6066   
Other liabilities0000000
Other undisclosed current liabilities1 01000
Total current liabilities:8177112
Noncurrent Liabilities
Long-term debt and lease obligation 6  666
Long-term debt, excluding current maturities 6  666
Other undisclosed noncurrent liabilities010 000
Total noncurrent liabilities:070 666
Total liabilities:8887778
Stockholders' equity
Stockholders' equity attributable to parent(6)(6)(5)(5)(5)(5)(5)
Common stock0000000
Additional paid in capital383383383383383383383
Accumulated deficit(389)(389)(388)(389)(388)(388)(388)
Total stockholders' equity:(6)(6)(5)(5)(5)(5)(5)
TOTAL LIABILITIES AND EQUITY:2232322

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Gross profit:1011110
Operating expenses(1)(1)(1)(2)(1)(1)(1)
Other undisclosed operating income   10  
Operating income (loss):(0)(1)0(0)00(1)
Interest and debt expense(0)(0)(0)(0)(0)(0)(3)
Net income (loss) available to common stockholders, diluted:(0)(1)0(1)00(3)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income (loss):(0)(1)0(1)00(3)
Comprehensive income (loss), net of tax, attributable to parent:(0)(1)0(1)00(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: